BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...

Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

Emergent BioSolutions (NYSE:EBS) has entered into an agreement for the exclusive commercial rights in the U.S. and Canada for ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has ...

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

(RTTNews) - Emergent BioSolutions (EBS), a life sciences company, on Tuesday announced that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada for ...

Kaseya said the mpox vaccine has been well received in countries that have deployed the vaccine, including in the DRC. He ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...